By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- New research on Biotechnology is the subject of a report. According to news reporting originating from Chongqing, People's Republic of China, by NewsRx correspondents, research stated, "As reported in the literature, the worldwide 5-year overall survival rate for patients with gastric cancer receiving surgical treatment in the progressive stage is less than 25%. Therefore, there is an urgent need for the development of novel therapeutic strategies."
Our news editors obtained a quote from the research from Chongqing Medical University, "Our preliminary studies demonstrated that proliferin-related protein (PRP) inhibits the proliferation of TM3 Leydig testicular cells. To evaluate whether PRP has antitumor effects in vitro and in vivo, we stably expressed PRP in SGC-7901 gastric carcinoma cells. PRP inhibited the proliferation and cell cycle progression of SCG-7901 cells, as determined by cell growth and cell cycle assays. Transwell experiments demonstrated that PRP inhibited the cell migration and invasion of SCG-7901 cells. Western blotting demonstrated that PRP-overexpressing cells had upregulated matrix metalloproteinase 9 (MMP-9) and downregulated tissue inhibitor of metalloproteinases-1 (TIMP-1). In a xenograft tumor formation assay using nude mice, tumors formed by PRP-overexpressing cells had significantly lower weights than those formed by control cells, and the tumor inhibitory rate reached 71.9%."
According to the news editors, the research concluded: "We demonstrated for the first time that PRP inhibits gastric carcinoma cell proliferation, motility, and tumorigenicity in vivo, suggesting that PRP may become an important target for the development of gastric cancer gene therapy."
For more information on this research see: Proliferin-related protein overexpression in SGC?7901 gastric cancer cells inhibits in vitro cell growth and tumorigenesis in nude mice. Oncology Reports, 2013;29(6):2243-8 (see also Biotechnology).
The news editors report that additional information may be obtained by contacting M. He, Institute of Life Sciences, The First Affiliated Hospital, Chongqing Medical University, Chongqing 400016, People's Taiwan. Additional authors for this research include L. Wang, J. Pu, Q. Yang, G. Li and J. Hao.
Keywords for this news article include: Asia, Biotechnology, Oncology, Chongqing, Bioengineering, Gastric Cancer, Gastroenterology, Cancer Gene Therapy, People's Republic of China.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC